{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:48:01Z","timestamp":1790740081173,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia\/lymphoma (ATLL) patients have an extremely poor prognosis, partly due to their immunosuppressive state. The majority of ATLL patients have leukemic cells with phenotype similar to Tregs, prompting suggestions that ATLL cells themselves have immunosuppressive functions. In this study, we detected CD39 expression on ATLL cells, particularly frequent on aggressive subtypes. CD39 and CD73 convert extracellular adenosine triphosphate (ATP) into adenosine, a key player in Tregs\u2019 immunosuppression. In vitro culture, both CD39<jats:sup>+<\/jats:sup>ATLL cells and normal Tregs converted rapidly extracellular ATP to AMP, which was disturbed by CD39 inhibitors, and was negated in the CD39 knockout MJ cell line. The proliferation of cocultured CD4<jats:sup>+<\/jats:sup>\/CD8<jats:sup>+<\/jats:sup>normal T cells was suppressed by CD39<jats:sup>+<\/jats:sup>MJ cells, but not by CD39 knockout MJ cells. Supplemented ATP was exhausted by an EG7-OVA T-cell line with stable CD39 induction, but not by mock. When these cell lines were subcutaneously transplanted into murine flanks, Poly(I:C) peritoneal administration reduced tumor size to 1\/3 in mock-transplanted tumors, but not in CD39 induced tumors. Overall, we found that ATLL cells express CD39 at a high rate, and our results suggest that this helps ATLL cells escape antitumor immunity through the extracellular ATPDase-Adenosine cascade. These findings will guide future clinical strategies for ATLL treatment.<\/jats:p>","DOI":"10.1038\/s41375-020-0788-y","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T15:02:40Z","timestamp":1584716560000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function"],"prefix":"10.1038","volume":"35","author":[{"given":"Yasuhiro","family":"Nagate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Ezoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4552-783X","authenticated-orcid":false,"given":"Daisuke","family":"Okuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Motooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Ichii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Kurashige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Shibayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Oritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Kanakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"788_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481\u201392.","journal-title":"Blood"},{"key":"788_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-2-16","volume":"2","author":"K Takatsuki","year":"2005","unstructured":"Takatsuki K. Discovery of adult T-cell leukemia. Retrovirology. 2005;2:16.","journal-title":"Retrovirology"},{"key":"788_CR3","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2169\/internalmedicine.54.1953","volume":"54","author":"N Kawano","year":"2015","unstructured":"Kawano N, Yoshida S, Kuriyama T, Tahara Y, Yamashita K, Nagahiro Y, et al. Clinical features and treatment outcomes of 81 patients with aggressive type adult T-cell leukemia-lymphoma at a single institution over a 7-year period (2006\u201312). Intern Med. 2015;54:1489\u201398.","journal-title":"Intern Med"},{"key":"788_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","volume":"79","author":"M Shimoyama","year":"1991","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T\u2010cell leukaemia\u2010lymphoma: a report from the Lymphoma Study Group (1984\u201387). Br J Haematol. 1991;79:428\u201337.","journal-title":"Br J Haematol"},{"key":"788_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4939-6872-5_15","volume":"1582","author":"R Nasr","year":"2017","unstructured":"Nasr R, Mar\u00e7ais A, Hermine O, Bazarbachi A. Overview of targeted therapies for adult T-cell leukemia\/lymphoma. Methods Mol Biol. 2017;1582:197\u2013216.","journal-title":"Methods Mol Biol"},{"key":"788_CR6","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jmv.22013","volume":"83","author":"M Ogata","year":"2011","unstructured":"Ogata M, Satou T, Kawano R, Yoshikawa T, Ikewaki J, Kohno K, et al. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for Adult T cell leukemia. J Med Virol. 2011;83:702\u20139.","journal-title":"J Med Virol"},{"key":"788_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-46","volume":"9","author":"Y Satou","year":"2012","unstructured":"Satou Y, Utsunomiya A, Tanabe J, Nakagawa M, Nosaka K, Matsuoka M. HTLV-1 modulates the frequency and phenotype of FoxP3+CD4+ T cells in virus-infected individuals. Retrovirology. 2012;9:46.","journal-title":"Retrovirology"},{"key":"788_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2141.2004.04999.x","volume":"126","author":"K Karube","year":"2004","unstructured":"Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, et al. Expression of FoxP3, a key molecule in CD4+CD25+ regulatory T cells, in adult T-cell leukaemia\/lymphoma cells. Br J Haematol. 2004;126:81\u201384.","journal-title":"Br J Haematol"},{"key":"788_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/intimm\/dxh366","volume":"18","author":"S Chen","year":"2005","unstructured":"Chen S, Ishii N, Ine S, Ikeda S, Fujimura T, Ndhlovu LC, et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol. 2005;18:269\u201377.","journal-title":"Int Immunol"},{"key":"788_CR10","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/ijc.22536","volume":"120","author":"H Yano","year":"2007","unstructured":"Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, et al. Regulatory T-cell function of adult T-cell leukemia\/lymphoma cells. Int J Cancer. 2007;120:2052\u20137.","journal-title":"Int J Cancer"},{"key":"788_CR11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1349-7006.2007.00646.x","volume":"99","author":"T Shimauchi","year":"2008","unstructured":"Shimauchi T, Kabashima K, Tokura Y. Adult T-cell leukemia\/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Sci. 2008;99:98\u2013106.","journal-title":"Cancer Sci"},{"key":"788_CR12","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1002\/ijc.24664","volume":"125","author":"F Toulza","year":"2009","unstructured":"Toulza F, Nosaka K, Takiguchi M, Pagliuca T, Mitsuya H, Tanaka Y, et al. FoxP3+ regulatory T cells are distinct from leukemia cells in HTLV-1-associated adult T-cell leukemia. Int J Cancer. 2009;125:2375\u201382.","journal-title":"Int J Cancer"},{"key":"788_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","volume":"30","author":"M Miyara","year":"2009","unstructured":"Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30:899\u2013911.","journal-title":"Immunity"},{"key":"788_CR14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/modpathol.2008.25","volume":"21","author":"K Karube","year":"2008","unstructured":"Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, et al. The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia\/lymphoma. Mod Pathol. 2008;21:617\u201325.","journal-title":"Mod Pathol"},{"key":"788_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s12010-017-2406-7","volume":"182","author":"SA Ghezeldasht","year":"2017","unstructured":"Ghezeldasht SA, Sadeghian H, Azarpazhooh MR, Shamsian SAA, Rafatpanah H, Mahmoodi M, et al. Evaluation of T regulatory lymphocytes transcription factors in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients. Appl Biochem Biotechnol. 2017;182:1403\u201314.","journal-title":"Appl Biochem Biotechnol"},{"key":"788_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.clml.2011.06.005","volume":"11","author":"D Pulte","year":"2011","unstructured":"Pulte D, Furman RR, Broekman MJ, Drosopoulos JHF, Ballard HS, Olson KE, et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011;11:367\u201372.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"788_CR17","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.3892\/ol.2016.5189","volume":"12","author":"XY Cai","year":"2016","unstructured":"Cai XY, Wang XF, Li J, Dong JN, Liu JQ, Li NP, et al. High expression of CD39 in gastric cancer reduces patient outcome following radical resection. Oncol Lett. 2016;12:4080\u20136.","journal-title":"Oncol Lett"},{"key":"788_CR18","doi-asserted-by":"publisher","first-page":"S457","DOI":"10.1038\/bjp.2008.23","volume":"153","author":"M Sitkovsky","year":"2008","unstructured":"Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A. Adenosine A2A receptor antagonists: Blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol. 2008;153:S457\u2013464.","journal-title":"Br J Pharmacol"},{"key":"788_CR19","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1074\/jbc.M109.047423","volume":"285","author":"M Mandapathil","year":"2010","unstructured":"Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+regulatory T Cells. J Biol Chem. 2010;285:7176\u201386.","journal-title":"J Biol Chem"},{"key":"788_CR20","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","volume":"204","author":"S Deaglio","year":"2007","unstructured":"Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204:1257\u201365.","journal-title":"J Exp Med"},{"key":"788_CR21","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.4049\/jimmunol.177.10.6780","volume":"177","author":"JJ Kobie","year":"2006","unstructured":"Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TRT. Regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5\u2019-adenosine monophosphate to adenosine. J Immunol. 2006;177:6780\u20136.","journal-title":"J Immunol"},{"key":"788_CR22","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2006-12-064527","volume":"110","author":"G Borsellino","year":"2007","unstructured":"Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225\u201332.","journal-title":"Blood"},{"key":"788_CR23","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1016\/j.celrep.2018.05.042","volume":"23","author":"Y Doi","year":"2018","unstructured":"Doi Y, Yokota T, Satoh Y, Okuzaki D, Tokunaga M, Ishibashi T, et al. Variable SATB1 levels regulate hematopoietic stem cell heterogeneity with distinct lineage fate. Cell Rep. 2018;23:3223\u201335.","journal-title":"Cell Rep."},{"key":"788_CR24","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-13-3169","volume":"20","author":"S Kobayashi","year":"2014","unstructured":"Kobayashi S, Nakano K, Watanabe E, Ishigaki T, Ohno N, Yuji K, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia\/lymphoma. Clin Cancer Res. 2014;20:2851\u201361.","journal-title":"Clin Cancer Res"},{"key":"788_CR25","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nrc3613","volume":"13","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Blandizzi C, Pacher P, Hask\u00f3 G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13:842\u201357.","journal-title":"Nat Rev Cancer."},{"key":"788_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139.","journal-title":"Nat Med"},{"key":"788_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.immuni.2007.04.017","volume":"27","author":"T Yamaguchi","year":"2007","unstructured":"Yamaguchi T, Hirota K, Nagahama K, Ohkawa K, Takahashi T, Nomura T, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity. 2007;27:145\u201359.","journal-title":"Immunity"},{"key":"788_CR28","doi-asserted-by":"publisher","first-page":"17945","DOI":"10.1073\/pnas.1316796110","volume":"110","author":"D Sugiyama","year":"2013","unstructured":"Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci. 2013;110:17945\u201351790.","journal-title":"Proc Natl Acad Sci"},{"key":"788_CR29","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","volume":"127","author":"H Nishikawa","year":"2010","unstructured":"Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010;127:759\u201367.","journal-title":"Int J Cancer"},{"key":"788_CR30","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood.V97.10.3177","volume":"97","author":"JI Yasunaga","year":"2001","unstructured":"Yasunaga JI, Sakai T, Nosaka K, Etoh KI, Tamiya S, Koga S, et al. Impaired production of naive T lymphocytes in human T-cell leukemia virus type I-infected individuals: its implications in the immunodeficient state. Blood. 2001;97:3177\u201383.","journal-title":"Blood"},{"key":"788_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev.immunol.15.1.15","volume":"15","author":"T Uchiyama","year":"1997","unstructured":"Uchiyama T. Human T cell leukemia virus type 1 (HTLV-1) and human diseases. Annu Rev Immunol. 1997;15:15\u201337.","journal-title":"Annu Rev Immunol"},{"key":"788_CR32","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","volume":"129","author":"T Watanabe","year":"2017","unstructured":"Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood 2017;129:1071\u201381.","journal-title":"Blood"},{"key":"788_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1023\/A:1014471500757","volume":"22","author":"K Tsukasaki","year":"2002","unstructured":"Tsukasaki K. Genetic instability of adult T-cell leukemia\/lymphoma by comparative genomic hybridization analysis. J Clin Immunol. 2002;22:57\u201363.","journal-title":"J Clin Immunol"},{"key":"788_CR34","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood.V88.5.1755.1755","volume":"88","author":"L Airas","year":"1996","unstructured":"Airas L, Jalkanen S. CD73 mediates adhesion of B cells to follicular dendritic cells. Blood. 1996;88:1755\u201364.","journal-title":"Blood"},{"key":"788_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cei.12354","volume":"177","author":"PJ Schuler","year":"2014","unstructured":"Schuler PJ, Saze Z, Hong CS, Muller L, Gillespie DG, Cheng D, et al. Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol. 2014;177:531\u201343.","journal-title":"Clin Exp Immunol"},{"key":"788_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/10428194.2014.907893","volume":"56","author":"NK Abousamra","year":"2015","unstructured":"Abousamra NK, Salah El-Din M, Hamza Elzahaf E, Esmael ME. Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1\/CD39) as a new prognostic marker in chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56:113\u20139.","journal-title":"Leuk Lymphoma"},{"key":"788_CR37","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/j.1600-6143.2010.03291.x","volume":"10","author":"KM Dwyer","year":"2010","unstructured":"Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, et al. Expression of CD39 by human peripheral blood CD4+CD25+T cells denotes a regulatory memory phenotype. Am J Transpl. 2010;10:2410\u201320.","journal-title":"Am J Transpl"},{"key":"788_CR38","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","volume":"78","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Li L, Wang L, Li J, Fan Z, Yang L, et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 2018;78:1779\u201381.","journal-title":"Cancer Res"},{"key":"788_CR39","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Taniwaki M, Ando K, Tobinai K, Fujimoto K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral and cutaneous T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157\u201363.","journal-title":"J Clin Oncol"},{"key":"788_CR40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0788-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0788-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T16:38:33Z","timestamp":1722616713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0788-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0788-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"15 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}